Gerresheimer's Survival Bid Hinges on Swift Sale of US Unit
21.04.2026 - 07:33:11 | boerse-global.de
A lifeline from creditors has given Gerresheimer precious breathing room, but the Düsseldorf-based pharmaceutical packaging specialist now faces a critical race against time. The company's immediate future depends on successfully selling its US subsidiary, Centor, a move designed to shore up a balance sheet strained by delayed financial reporting and ongoing investigations.
The sale process, managed by investment bank Morgan Stanley, is already underway with more than ten potential buyers reportedly examining the books. Gerresheimer aims to finalize the transaction within the current year. The unit, which manufactures packaging systems for prescription drugs in the US, was acquired roughly a decade ago for $725 million. CFO Wolf Lehmann has identified its divestment as a top priority for reducing the company's debt burden.
This urgency follows a crucial agreement with lenders in mid-April. Holders of approximately 96% of the company's 870 million euros in Schuldschein loans agreed to extend key deadlines. The requirement for Gerresheimer to submit its audited 2025 financial statements has been pushed back to September 30, 2026. Furthermore, major covenant tests related to leverage ratios have been suspended until the end of the third quarter.
Should investors sell immediately? Or is it worth buying Gerresheimer?
This financial reprieve is vital for interim CEO Uwe Röhrhoff to navigate concurrent challenges. The company is working to complete an internal probe into business transactions from 2024 and 2025, alongside a separate review by German financial regulator BaFin. The delayed reporting stemming from these issues led to Gerresheimer's removal from the SDAX index in April.
News of the creditor deal ignited a sharp, if partial, stock recovery. Shares surged almost 20% on a weekly basis, closing at 21.00 euros on Monday after briefly touching 21.80 euros. This rally merely dented a longer-term decline; the stock remains down about 24% since January and trades nearly 60% below its level from a year ago.
Despite the corporate turbulence, Gerresheimer's underlying business shows resilience. The company forecasts 2026 revenue of up to 2.4 billion euros, with an adjusted operating margin around 18%. Order intake remains solid, indicating core operations are intact.
Analysts stress that sustained market confidence is contingent on two deliverables. The first is a swift and successful conclusion to the Centor sale, which would directly improve the capital structure. The second is the long-awaited publication of the audited annual report, now targeted for June 2026. Until these milestones are met, the path to normalization remains fraught with hard deadlines.
Ad
Gerresheimer Stock: New Analysis - 21 April
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Gerresheimers Aktien ein!
Für. Immer. Kostenlos.
